KROS Nasdaq Pharmaceutical Preparations Financials FY2019βFY2025
Keros Therapeutics, Inc. had $244M of revenue in fiscal 2025.
Last close Β· Oct 23, 2026
$11.28
0.6%Hi! I read Keros Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Does it make a profit?
35.7%
Yes. It keeps 35.7% of every sale as profit.
Does profit turn into cash?
43.4%
Yes. 43.4% of sales ends up as free cash.
How healthy are the accounts?
5 / 7
Mixed. It passes 5 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Keros Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 3, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 14, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Mar 4, 2026 | Q4 '25 | After the market closes | 8-K β |
| Oct 15, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 6, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 6, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 26, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 6, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Keros Therapeutics, Inc. had $244M of revenue in fiscal 2025. Its operating margin was 27.7%: of every 100 in sales, about 28 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Keros Therapeutics, Inc. made $87.0M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $106M in fiscal 2025, 43.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Keros Therapeutics, Inc. returned $375M to shareholders in fiscal 2025, 354% of free cash flow. The diluted share count rose 1.1%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Keros Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $230M | $279M | $331M | $560M | $287M |
| Interest coverage | β14,093.3x | β114,790.0x | β | β | β |
| Current ratio | 21.2x | 17.3x | 14.2x | 21.5x | 15.5x |
| Quick ratio | 21.2x | 17.3x | 14.2x | 21.5x | 15.5x |
| Total assets | $255M | $307M | $370M | $616M | $338M |
| Total liabilities | $12.1M | $29.4M | $37.8M | $44.3M | $34.9M |
| Shareholders' equity | $243M | $277M | $332M | $572M | $303M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Keros Therapeutics, Inc. passes 5 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 1 / 7 | 1 / 7 | 2 / 7 | 3 / 7 | 5 / 7 |
| Accruals ratio | 33.4% | β6.0% | 1.3% | β12.3% | β8.4% | β5.4% | β4.3% |
| Altman Z'' | β11.62 | 39.98 | 24.24 | 10.74 | 8.50 | 14.21 | 11.55 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $10.0M | $0.0M | $20.1M | $0.0M | $0.2M | $0.0M | $244M |
| Research and development | $17.4M | $33.9M | $55.1M | $87.3M | $135M | $174M | $130M |
| Operating income | β$10.6M | β$46.7M | β$56.4M | β$115M | β$170M | β$211M | $67.6M |
| Interest expense | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Pretax income | β$12.3M | β$45.5M | β$56.7M | β$105M | β$153M | β$187M | $91.9M |
| Income tax | $0.0M | β$0.2M | $2.0M | $0.0M | $0.0M | $0.3M | $4.9M |
| Net income | β$12.3M | β$45.4M | β$58.7M | β$105M | β$153M | β$187M | $87.0M |
| Net income to common | β$14.1M | β$45.4M | β$58.7M | β$105M | β$153M | β$187M | $87.0M |
| Diluted EPS | β$6.08 | β$2.93 | β$2.52 | β$4.15 | β$5.20 | β$5.00 | $2.30 |
| Diluted shares | 0.00B | 0.02B | 0.02B | 0.03B | 0.03B | 0.04B | 0.04B |
| Cash flow | |||||||
| Cash from operations | β$16.0M | β$36.9M | β$62.1M | β$70.1M | β$125M | β$161M | $108M |
| Capital expenditure | $0.3M | $0.3M | $1.0M | $1.2M | $2.5M | $1.9M | $1.6M |
| Free cash flow | β$16.3M | β$37.2M | β$63.2M | β$71.3M | β$127M | β$163M | $106M |
| Depreciation and amortization | $0.2M | $0.3M | $0.4M | $0.7M | $0.8M | $1.2M | $1.5M |
| Stock-based compensation | $0.1M | $4.1M | $11.7M | $18.7M | $28.8M | $34.9M | $28.7M |
| Share buybacks | β | β | β | β | β | $0.0M | $375M |
| Dividends and buybacks | β | β | β | β | β | $0.0M | $375M |
| Balance sheet | |||||||
| Cash and short-term investments | $7.0M | $266M | $230M | $279M | $331M | $560M | $287M |
| Current assets | $8.9M | $268M | $251M | $286M | $347M | $589M | $315M |
| Current liabilities | $4.5M | $7.2M | $11.8M | $16.5M | $24.4M | $27.5M | $20.4M |
| Property and equipment, net | $0.7M | $0.7M | $1.3M | $2.0M | $4.1M | $4.2M | $4.3M |
| Total assets | $11.0M | $269M | $255M | $307M | $370M | $616M | $338M |
| Total liabilities | $10.5M | $7.7M | $12.1M | $29.4M | $37.8M | $44.3M | $34.9M |
| Preferred stock | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$19.4M | $262M | $243M | $277M | $332M | $572M | $303M |
| Margins | |||||||
| Operating margin | β105.6% | β | β280.5% | β | β112,543.7% | β | 27.7% |
| EBITDA margin | β103.6% | β | β278.6% | β | β112,004.0% | β | 28.3% |
| Net margin | β123.4% | β | β292.3% | β | β101,319.2% | β | 35.7% |
| FCF margin | β162.7% | β | β314.3% | β | β84,087.4% | β | 43.4% |
| Returns | |||||||
| Return on capital employed | β163.3% | β17.8% | β23.2% | β39.6% | β49.2% | β35.8% | 21.3% |
| Return on equity | β | β37.4% | β23.3% | β40.2% | β50.2% | β41.5% | 19.9% |
| Return on assets | β112.6% | β32.4% | β22.4% | β37.3% | β45.2% | β38.0% | 18.2% |
| Return on tangible equity | β | β17.3% | β24.2% | β37.7% | β46.1% | β32.8% | 28.7% |
| Growth | |||||||
| Revenue growth | β | β100.0% | β | β100.0% | β | β100.0% | β |
| Share count change | β | 566.4% | 50.5% | 8.2% | 16.7% | 27.1% | 1.1% |
| Financial health | |||||||
| Interest coverage | β | β7,776.2x | β14,093.3x | β114,790.0x | β | β | β |
| Current ratio | 2.0x | 37.3x | 21.2x | 17.3x | 14.2x | 21.5x | 15.5x |
| Quick ratio | 2.0x | 37.3x | 21.2x | 17.3x | 14.2x | 21.5x | 15.5x |
| Capital allocation | |||||||
| Capex / revenue | 2.7% | β | 5.1% | β | 1,631.8% | β | 0.6% |
| Stock comp / revenue | 0.6% | β | 58.3% | β | 19,048.3% | β | 11.8% |
| Payouts / FCF | β | β | β | β | β | β | 353.9% |
| Quality scores | |||||||
| Piotroski F-score | β | 3.0 | 1.0 | 1.0 | 2.0 | 3.0 | 5.0 |
| Altman Z'' | β11.6 | 40.0 | 24.2 | 10.7 | 8.5 | 14.2 | 11.5 |
| Accruals ratio | 33.4% | β6.0% | 1.3% | β12.3% | β8.4% | β5.4% | β4.3% |
Source: SEC EDGAR XBRL filings (CIK 0001664710). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
